Orexo AB (OSTO:ORX) Other Financing : kr-21.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Orexo AB Other Financing?

Orexo AB's Other Financing for the three months ended in Dec. 2023 was kr-21.4 Mil.

Orexo AB's Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 was kr-21.4 Mil.

Orexo AB Other Financing Historical Data

The historical data trend for Orexo AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Other Financing Chart

Orexo AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Financing

Get a 7-Day Free Trial

0.10

Orexo AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Financing	Get a 7-Day Free Trial															-21.40	-	-	-	-21.40

Orexo AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-21.4 Mil.

Orexo AB Other Financing Related Terms

Thank you for viewing the detailed overview of Orexo AB's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB (OSTO:ORX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OSTO:ORX) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

ORXOY:USA ORXOF:USA 0H19:UK C5G:Germany

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments US Pharma, Digital Therapeutics (DTx) and HQ & Pipeline. The majority is from the US Pharma segment. Geographically, the majority is derived from the United States. US Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline include the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB (OSTO:ORX) Headlines

No Headlines